Page last updated: 2024-11-06

lysergic acid diethylamide and Basal Ganglia Diseases

lysergic acid diethylamide has been researched along with Basal Ganglia Diseases in 1 studies

Lysergic Acid Diethylamide: Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood.
lysergic acid diethylamide : An ergoline alkaloid arising from formal condensation of lysergic acid with diethylamine.

Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Messiha, FS1
Larson, JW1

Other Studies

1 other study available for lysergic acid diethylamide and Basal Ganglia Diseases

ArticleYear
Biochemical changes associated with drug-produced alterations in motor function and the psyche: a possible underlying mechanism.
    Proceedings of the Western Pharmacology Society, 1977, Volume: 20

    Topics: Adult; Basal Ganglia Diseases; Cannabis; Chlorpromazine; Dopamine; Homovanillic Acid; Humans; Lyserg

1977